Voglibose

From Wikipedia, the free encyclopedia

Voglibose
Systematic (IUPAC) name
(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)- 1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
Identifiers
CAS number	83480-29-9
ATC code	A10BF03
PubChem	444020
Chemical data
Formula	C10H21NO7
Mol. mass	267.28 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Voglibose (INN and USAN) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus.

Diabetes is chronic metabolic disorder characterised by hyperglycemia which is due to relative or absolute deficiency of insulin or insulin resistance.

PPHG is termed as Post Prandial Hyperglycemia which is primarily due to first phase insulin secretion. Alpha glucosidase inhibitor is one agent which delays the glucose absorption at the intestine level and thereby prevents sudden surge of glucose post meal.

There are three molecules which belong to this class namely, Acarbose, Miglitol and Voglibose. Voglibose is the latest molecule in this class. Voglibose scores over both Acarbose and MIglitol in terms of potency and side effect profile.

There are several trials supporting the use of Voglibose in the management of PPHG. Also, it has been established that it is PPHG not FPG which is marker of cardiovascular disorders associeted with diabetes. So, controlling PPHG is imperative and Voglibose is indicated for the management of PPHG.

[edit] External links

• voglibose.com
• diabetesincontrol.com
• diabetesjournals.org
• Ranbaxy announcement

v • d • e Oral antidiabetic drugs and Insulin analogs (A10) Biguanides Metformin Sulfonylureas Carbutamide, Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide Alpha-glucosidase inhibitors Acarbose, Miglitol, Voglibose Thiazolidinediones (TZD) Pioglitazone, Rivoglitazone†, Rosiglitazone, Troglitazone‡ Meglitinides Nateglinide, Repaglinide, Mitiglinide Dipeptidyl peptidase-4 (DPP-4) inhibitors Alogliptin†, Saxagliptin†, Sitagliptin, Vildagliptin Glucagon-like peptide-1 analog Exenatide, Liraglutide†, Albiglutide† Amylin analog Pramlintide Insulin analogs fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir), Inhalable insulin (Exubera) Dual PPAR agonists Aleglitazar†, Muraglitazar§, Tesaglitazar§ SGLT2 inhibitor Dapagliflozin†, Remogliflozin†, Sergliflozin† †Undergoing clinical trials. ‡ Withdrawn from market. §Development halted.